Red Flags

Diagnosis is key

To reduce morbidity, choose the best treatment option and limit recurrence and / or complications.

Most of the symptoms seen in patients with acute uncomplicated cystitis are typical but not specific

Diagnosis logo

The Acute Cystitis Symptom Score (ACSS) questionnaire is used to:

  • Promote (self-) diagnosis and seek for medical advice
  • Help differentiate from other urogenital disorders
  • Assess the severity and impact on QOL
  • Monitor treatment efficacy

Some patient profiles are more at risk / prone to recurrence.
Use the LUTIRE test to predict your patient’s risk

Women who:

at risk women logo
  • Sexually active women (risk increases with number of partners)
  • Gram-negative pathogen infections
  • Postmenopausal women
  • Constipation
  • Previous treatment of ABU

Side effects

antibiotics side effects logo
  • Most common: antibiotic-associated diarrhoea (2–25%)
  • Antibiotic prophylaxis studies are generally old and efficacy results might be outdated due to increasing rates of resistance, as well as unlisted side effects due to their broader, prolonged or chronic use, including collateral damages

Aminopenicillins & fluroquinolones
(Should not be used)

  • No longer suitable for antimicrobial therapy of uncomplicated UTIs because of negative ecological effects and high resistance rates worldwide
  • Fluoroquinolones can also have serious side effects including tendon rupture, psychological and cardiac issues

Fosfomycin

  • Serious adverse events such as aplastic anaemia, anaphylaxis, and liver toxicities are infrequently reported
  • The most frequently reported adverse events are rash, peripheral phlebitis, hypokalaemia and gastrointestinal disorders

Nitrofurantoin

  • Increased risk for adverse events (neurogenic, hepatic and pulmonary) compared to trimethoprim and methenamine
  • Should be used with caution in those with renal impairment
  • Should be avoided at term in pregnancy (risk of neonatal haemolysis)
  • Adults (especially the elderly) and children on long-term therapy should be monitored for conditionally used liver function and pulmonary symptoms

Trimethoprim (conditionally)

  • Causes teratogenic risk in the 1st trimester of pregnancy and is contraindicated in pregnant women
  • Trimethoprim is usually prescribed as Co-trimoxazole, which has the following adverse effects: dermatological, hematological and gastrointestinal side effects, without providing an acceptable added benefit

Antimicrobial resistance is one of the biggest threats to global health

  • Accelerated by the misuse and overuse of antibiotics, as well as poor infection prevention and control
  • 25% of all antibiotic prescriptions are for UTIs
  • Costs the European Union €1.5 billion in healthcare expenses and lost productivity each year
  • Can lead to more severe infections, longer hospital stays and increased mortality
  • Some infections for which therapy is now available might become untreatable

Alternatives to antimicrobials for the prevention of rUTIs aim to reduce the crisis of antimicrobial resistance and pave the way for a new era in the management of rUTIs.

Bacterial reservoirs

  • Infecting strains can invade bladder epithelial cells (forming bacterial reservoirs) and subsequently re-emerge to infect the bladder and cause another case of cystitis
  • The main disease reservoirs for urogenital infections are the vagina and the gut, but reservoirs can also be found in the urethra
  • In UTIs caused by uropathogenic E. coli (UPEC), more than 60% of recurrences can be attributed to the original infecting strain


What links antimicrobials to bacterial reservoirs and rUTIs?

  • A decrease in peroxide-producing Lactobacillli may predispose pathogenic enteric bacteria to increased colonisation
  • Formation of intracellular bacterial communities not sensitive to antibiotics
  • A change in the glycosaminoglycan barrier of the urothelium, which may make an individual more susceptible to enteropathogenic infection

Microbiome impairment

  • A resident microbial community in the human urinary tract has recently been identified, consisting of many genra and species, such as Lactobacillus crispatus
  • Commensal species within the urinary and urogenital tract that are part of the local microbiota may act to protect against colonisation with uropathogens for bacterial displacement
  • Both the infection itself and treatment strategies, such as antimicrobial therapy, can disrupt the urinary microbiome and affect the local immune homeostasis and healthy status


Diagnostic, prognostic and therapeutic options for the management of UTIs may soon incorporate efforts to measure, restore and/or preserve the native, healthy ecology of the urinary microbiota.

Acute Kidney Injury (AKI)

Complications

Complicated UT Is

Complicated UTIs may be associated with sepsis, and cause sudden deterioration of renal function

Complications

Sepsis

Sepsis is one of the most common triggers of AKI

Complications

Septic shock

60% patients with septic shock develop AKI

Complications

Complicated UTI patients

12.3% of complicated UTI patients develop AKI

Complications

High morbidity

AKI is associated with high morbidity and mortality

What are the risk factors for development of AKI in UTI patients?

  • Diabetes mellitus
  • Upper UTI
  • Febrile or septic shock during hospitalisation
  • Impaired baseline renal function


Physicians should pay extra attention to UTI patients at risk of AKI.

Pyelonephritis

Septic shock

The development of cystitis is probably the initial step in the pathogenic process culminating in acute pyelonephritis

Pyelonephritis

E coli

E.coli is the predominant infecting microorganism (85% of cases), similar to proportions reported for cystitis

What are the risk factors for pyelonephritis?

  • Anatomic abnormalities fo urinary tract urolithiasis
  • Diabetes mellitus


Patients with recurrent upper UTIs should be referred for further specialist investigation and management.

Sepsis

Depending on underlying conditions, e.g. obstructive pyelonephritis, UTIs can progress to sepsis and septic shock.

UTI patients

of UTI patients can contract septic shock depending on underlying conditions

Sepsis

Depending on underlying conditions, e.g. obstructive pyelonephritis, UTIs can progress to sepsis and septic shock.

Urosepsis cases

of urosepsis cases can result in death in specific patient groups

What factors can cause septic shock among UTI patients?

  • Health care-associated infection
  • Indwelling urinary catheter use
  • Congestive heart failure
  • Liver cirrhosis
  • History of coronary artery disease
  • AKI


Recognition of risk factors for complications and treatment failure with early intervention of broad-spectrum antimicrobials may significantly improve the outcome of sepsis in UTI patients.

Quality of life

  • Although uncomplicated cystitis in women is considered to be a relatively benign and self-limiting condition, it can have a substantial negative effect on patients.
  • Any illness, even if short-lived and not life threatening, can have an important impact on the patient’s daily activities, social functioning and wellbeing.
  • The sudden, unforeseeable, and distressing nature of painful UTI episodes often cause patients anxiety. The resulting social handicap can lead to clinical symptoms of depression.
  • Acute cystitis, as well as failure of the treatment, and adverse effects of antibiotics can reduce women’s quality of life.

As UTIs seem to be independently associated with a negative impact on quality of life or poor subjective wellbeing, more focus is needed on prevention, diagnosis and treatment of UTIs.

OM Pharma Logo

The RECAP board is a panel of international experts in urological infections. The opinions presented within this educational material are those of the RECAP board and not those of OM Pharma. Members of the RECAP board include: Jose Tiran Saucedo (Mexico), Yvette León (Mexico), Gernot Bonkat (Switzerland), Kurt G. Naber (Germany), Florian ME. Wagenlehner (Germany), J C. Nickel (Canada), Flavia Rossi (Brazil), Enrique Ubertazzi (Argentina), Agnaldo L. da Silva Filho (Brazil), Tamara S. Perepanova (Russia), Bela Köves (Hungary) & Tommaso Cai (Italy).

Patient version : MED-HQ-UV-2100071 / HCP version : MED-HQ-UV-2100070
Date of preparation: December 2021